Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Relapsing Remitting Multiple Sclerosis peptide trials
8 selected ClinicalTrials.gov records carrying the official condition label Relapsing Remitting Multiple Sclerosis. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
8 selected records.
1 profiles.
2011–2021 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 25 selected PubMed records and 11 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Relapsing Remitting Multiple Sclerosis unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00211887
PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- April 3, 2014
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00337779
PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- October 10, 2011
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00451204
PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- June 16, 2016
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Glatiramer acetate · 2021-12-09
ClinicalTrials.gov record NCT01067521
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2017-03-14
ClinicalTrials.gov record NCT00947752
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2016-06-16
ClinicalTrials.gov record NCT00451204
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2015-06-22
ClinicalTrials.gov record NCT01317004
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2014-08-08
ClinicalTrials.gov record NCT01534182
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2014-04-03
ClinicalTrials.gov record NCT00211887
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2013-09-19
ClinicalTrials.gov record NCT01071083
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2011-10-10
ClinicalTrials.gov record NCT00337779
Completed at the retained observation.
Open attributed record →